4.3 Review

Regulatory Considerations in the Design and Manufacturing of Implantable 3D-Printed Medical Devices

期刊

CTS-CLINICAL AND TRANSLATIONAL SCIENCE
卷 8, 期 5, 页码 594-600

出版社

WILEY
DOI: 10.1111/cts.12315

关键词

FDA; surgery; translational research; computers; imaging; methodology

资金

  1. NIH [R21 HD076370-01, T32 DC005356-12]
  2. National Center for Advancing Translational Sciences of the National Institutes of Health [2UL1TR000433]

向作者/读者索取更多资源

Three-dimensional (3D) printing, or additive manufacturing, technology has rapidly penetrated the medical device industry over the past several years, and innovative groups have harnessed it to create devices with unique composition, structure, and customizability. These distinctive capabilities afforded by 3D printing have introduced new regulatory challenges. The customizability of 3D-printed devices introduces new complexities when drafting a design control model for FDA consideration of market approval. The customizability and unique build processes of 3D-printed medical devices pose unique challenges in meeting regulatory standards related to the manufacturing quality assurance. Consistent material powder properties and optimal printing parameters such as build orientation and laser power must be addressed and communicated to the FDA to ensure a quality build. Postprinting considerations unique to 3D-printed devices, such as cleaning, finishing and sterilization are also discussed. In this manuscript we illustrate how such regulatory hurdles can be navigated by discussing our experience with our group's 3D-printed bioresorbable implantable device.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据